Last reviewed · How we verify
Standard dose topiramate
Topiramate blocks sodium channels, enhances GABA activity, and inhibits carbonic anhydrase to reduce neuronal excitability and prevent seizures.
Topiramate blocks sodium channels, enhances GABA activity, and inhibits carbonic anhydrase to reduce neuronal excitability and prevent seizures. Used for Epilepsy / seizure disorders, Migraine prophylaxis, Bipolar disorder (off-label).
At a glance
| Generic name | Standard dose topiramate |
|---|---|
| Also known as | Standard topiramate |
| Sponsor | Mario Negri Institute for Pharmacological Research |
| Drug class | Anticonvulsant / Antiepileptic agent |
| Target | Voltage-gated sodium channels, GABA-A receptors, carbonic anhydrase |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
Topiramate works through multiple mechanisms: it stabilizes neuronal membranes by blocking voltage-gated sodium channels, potentiates the inhibitory neurotransmitter GABA at GABA-A receptors, and inhibits carbonic anhydrase enzymes. These combined effects reduce abnormal electrical activity in the brain, making it effective for seizure control and migraine prevention.
Approved indications
- Epilepsy / seizure disorders
- Migraine prophylaxis
- Bipolar disorder (off-label)
Common side effects
- Cognitive impairment / memory problems
- Paresthesia
- Weight loss
- Fatigue
- Dizziness
- Acute myopia / angle-closure glaucoma
- Metabolic acidosis
Key clinical trials
- Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed, Previously Untreated Epilepsy(STANDLOW) (PHASE4)
- Medications After Adolescent Bariatric Surgery (PHASE2)
- Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds (PHASE2)
- Fast Acute Sedation at Intensive Care vs. High-dose i.v. Anti-seizure Medication for Treatment of Non-convulsive Status Epilepticus (FAST-trial) (PHASE3)
- Topiramate in Neonates Receiving Whole Body Cooling for Hypoxic Ischemic Encephalopathy (PHASE1, PHASE2)
- The Role of Migraine Prophylaxis Agent Topiramate in Treating Patients With Sudden Sensorineural Hearing Loss (PHASE2)
- Cognitive Side Effects of Commonly Prescribed Medications in Pediatric Migraine (NA)
- Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard dose topiramate CI brief — competitive landscape report
- Standard dose topiramate updates RSS · CI watch RSS
- Mario Negri Institute for Pharmacological Research portfolio CI